Vericiguat in Heart Failure

 Vericiguat in Heart Failure: Mechanism, Indications, Dosing, Evidence and Clinical Use

Vericiguat is an oral soluble guanylate cyclase (sGC) stimulator developed for patients with heart failure with reduced ejection fraction (HFrEF), particularly those who remain at high risk after a recent episode of worsening heart failure.

Unlike the four foundational therapies of HFrEF, vericiguat is generally considered an additional treatment for selected high-risk patients rather than routine first-line therapy for every patient with reduced ejection fraction.

Its clinical role became established largely through the VICTORIA trial, which demonstrated a reduction in the composite outcome of cardiovascular death or hospitalization for heart failure among patients with recently worsening HFrEF.

---

What Is Vericiguat?

Vericiguat is an oral soluble guanylate cyclase stimulator.

It acts on the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate (NO–sGC–cGMP) pathway, an important signaling pathway involved in vascular tone, myocardial function and cardiovascular homeostasis.

The drug is particularly relevant because this pathway becomes impaired in heart failure.

---

Why Target the NO–sGC–cGMP Pathway?

Under normal physiological conditions:

Nitric oxide (NO) → activates soluble guanylate cyclase (sGC) → increases cyclic GMP (cGMP)

cGMP contributes to:

• Vasodilation

• Improved vascular function

• Regulation of myocardial relaxation

• Reduction in vascular stiffness

• Modulation of myocardial remodeling

• Maintenance of cardiovascular homeostasis

In chronic heart failure, oxidative stress and endothelial dysfunction can reduce nitric oxide bioavailability.

The result is impaired sGC stimulation and decreased cGMP production.

Vericiguat attempts to restore signaling through this pathway.

---

Mechanism of Action of Vericiguat

Vericiguat stimulates soluble guanylate cyclase through two complementary mechanisms.

First, it directly stimulates sGC independently of nitric oxide.

Second, it sensitizes sGC to endogenous nitric oxide.

The overall result is increased intracellular cGMP.

In simplified form:

Reduced NO signaling in HF

↓

Reduced sGC activity

↓

Reduced cGMP

↓

Vascular and myocardial dysfunction

Vericiguat

↓

Stimulates sGC + increases sensitivity to NO

↓

↑ cGMP

↓

Improved cardiovascular signaling

This mechanism distinguishes vericiguat from the conventional neurohormonal therapies used in HFrEF.

---

Indications for Vericiguat

The most important clinical setting for vericiguat is symptomatic chronic HFrEF with a recent worsening heart failure event despite guideline-directed medical therapy (GDMT).

It may be considered in selected patients with:

• Symptomatic HFrEF

• Persistent high risk despite appropriate GDMT

• Recent worsening of heart failure

• Recent HF hospitalization or need for intravenous diuretic therapy

The VICTORIA trial studied patients with symptomatic chronic heart failure and an ejection fraction below 45% who had experienced a recent worsening heart failure event.

Therefore, vericiguat should not be viewed simply as another medication to prescribe to every patient with a low EF.

Its greatest clinical relevance is the patient who remains at substantial residual risk despite contemporary heart failure treatment.

---

What Does “Worsening Heart Failure” Mean?

This is an important concept when deciding whether vericiguat is appropriate.

Worsening heart failure generally refers to clinical deterioration significant enough to require escalation of treatment, particularly:

• Hospitalization for heart failure

or

• Outpatient administration of intravenous diuretics

These patients represent a particularly vulnerable population.

After an episode of worsening HF, the risk of another hospitalization and cardiovascular death increases substantially.

This high-risk period is where additional therapies such as vericiguat may have a role.

---

Vericiguat Is Not a Replacement for Foundational HFrEF Therapy

Before considering vericiguat, clinicians should optimize guideline-directed medical therapy whenever possible.

The four major foundational drug classes for HFrEF remain:

1. ARNI, ACE inhibitor or ARB

2. Evidence-based beta-blocker

3. Mineralocorticoid receptor antagonist (MRA)

4. SGLT2 inhibitor

These therapies have strong evidence supporting reductions in morbidity and/or mortality.

Vericiguat should generally be considered an additional therapy in an appropriately selected patient who remains at high risk despite optimized treatment.

---

The VICTORIA Trial

The landmark evidence supporting vericiguat comes from the VICTORIA trial:

“Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction.”

VICTORIA was a randomized, double-blind, placebo-controlled trial involving more than 5,000 patients with chronic symptomatic HFrEF and a recent worsening heart failure event.

The population was particularly important because these patients were at considerably higher risk than many patients enrolled in conventional chronic HF trials.

---

VICTORIA Trial Population

Important characteristics included:

• Symptomatic chronic heart failure

• NYHA functional class II–IV

• LVEF <45%

• Recent worsening heart failure

Patients had experienced either a recent hospitalization for heart failure or required intravenous diuretic therapy without hospitalization.

---

Primary Outcome of VICTORIA

The primary endpoint was a composite of:

Cardiovascular death or first hospitalization for heart failure.

Vericiguat significantly reduced the risk of the primary composite endpoint compared with placebo.

The benefit was driven predominantly by a reduction in heart failure hospitalization rather than a large isolated reduction in cardiovascular mortality.

This distinction is clinically important when discussing the expected benefit of therapy with patients.

---

Where Does Vericiguat Fit in Clinical Practice?

A practical way to think about vericiguat is:

Stable HFrEF

↓

Start and optimize foundational GDMT

↓

ARNI/ACEI/ARB + beta-blocker + MRA + SGLT2 inhibitor

↓

Patient remains symptomatic/high risk

↓

Recent HF hospitalization or worsening HF event

↓

Consider additional therapies based on phenotype

↓

Vericiguat may be considered

Therefore, a recent worsening HF episode is one of the strongest clues that a patient may be an appropriate candidate.

---

Vericiguat Dose

Vericiguat is administered once daily with food.

The usual starting dose is:

2.5 mg once daily

The dose is then approximately doubled every 2 weeks as tolerated:

2.5 mg once daily

↓

5 mg once daily

↓

10 mg once daily

The target maintenance dose is:

10 mg once daily

Blood pressure and clinical tolerance should be assessed during titration.

---

Why Should Vericiguat Be Taken With Food?

Administration with food improves drug exposure and reduces variability in absorption.

For this reason, patients should generally be instructed to take vericiguat with food rather than inconsistently switching between fed and fasting administration.

---

Blood Pressure and Vericiguat

Because vericiguat enhances the NO–sGC–cGMP pathway, vasodilation and reduction in blood pressure can occur.

Symptomatic hypotension is therefore an important consideration.

Before initiation and during dose titration, assess:

• Blood pressure

• Symptoms of dizziness or presyncope

• Volume status

• Other vasodilator medications

• Tolerance of existing HF therapy

Patients with low baseline blood pressure require particular caution.

---

Major Adverse Effects

The clinically important adverse effects associated with vericiguat include:

1. Hypotension

Blood pressure reduction may occur due to enhanced cGMP-mediated vasodilation.

Patients should be assessed for symptomatic hypotension, particularly during dose escalation.

2. Anemia

Anemia occurred more frequently in patients receiving vericiguat in clinical studies.

Hemoglobin assessment is therefore reasonable, particularly when anemia is already present or clinically suspected.

---

Contraindications

Pregnancy

Vericiguat can cause fetal harm and should not be used during pregnancy.

Pregnancy status and appropriate contraception should therefore be considered in patients with reproductive potential.

Concomitant Use With Other sGC Stimulators

Vericiguat should not be used concomitantly with another soluble guanylate cyclase stimulator.

An important example is riociguat.

Combining agents acting strongly on the same pathway may substantially increase adverse hemodynamic effects.

---

Vericiguat and PDE-5 Inhibitors

Concomitant administration with phosphodiesterase-5 inhibitors is not recommended because of the potential for excessive hypotension.

Examples of PDE-5 inhibitors include:

• Sildenafil

• Tadalafil

• Vardenafil

Both therapeutic approaches influence the NO–cGMP pathway and can enhance vasodilatory effects.

Therefore, the patient's complete medication list should be reviewed before starting vericiguat.

---

Vericiguat vs Sacubitril/Valsartan

These drugs should not be considered alternatives serving exactly the same purpose.

Sacubitril/valsartan is a foundational neurohormonal therapy for HFrEF and should generally be prioritized when appropriate.

Vericiguat acts through the NO–sGC–cGMP pathway and has a more selective role in patients with recent worsening HF despite appropriate background therapy.

In most eligible patients, the question is therefore not:

“ARNI or vericiguat?”

Instead, it is:

“Does this high-risk patient remain an appropriate candidate for vericiguat after foundational therapy has been optimized?”

---

Vericiguat vs SGLT2 Inhibitors

SGLT2 inhibitors such as dapagliflozin and empagliflozin are now foundational therapies for HFrEF.

Their use is supported across a broad spectrum of patients with heart failure.

Vericiguat has a narrower role.

It is particularly relevant to patients with HFrEF who have recently experienced worsening HF and remain at high risk.

Therefore, vericiguat should generally not displace an indicated SGLT2 inhibitor.

---

Vericiguat vs Ivabradine

These drugs target different patient phenotypes.

Ivabradine reduces heart rate through inhibition of the funny current (If) in the sinus node and is useful only in appropriately selected patients who remain in sinus rhythm with an elevated resting heart rate despite maximally tolerated beta-blocker therapy.

Vericiguat does not depend on sinus rhythm or an elevated heart rate for its mechanism.

Its selection is primarily driven by the presence of symptomatic HFrEF with recent worsening HF and persistent residual risk.

---

Which Patient Is an Ideal Candidate?

A typical patient in whom vericiguat might be considered could have:

• HFrEF

• Persistent NYHA II–IV symptoms

• Recent HF hospitalization

• Appropriate background GDMT

• Persistent high risk of recurrent HF hospitalization

• Adequate blood pressure to tolerate additional therapy

• No pregnancy

• No concomitant sGC stimulator

The decision should always be individualized.

---

Monitoring After Starting Vericiguat

Clinical follow-up should focus particularly on:

Blood pressure

Look for symptomatic hypotension, dizziness, presyncope or syncope.

Hemoglobin

Consider monitoring for development or worsening of anemia.

Clinical congestion

Continue assessment of volume status and adjust diuretic therapy according to clinical requirements.

Heart failure symptoms

Monitor NYHA functional class, exercise tolerance and evidence of recurrent deterioration.

Medication review

Ensure that interacting medications, particularly another sGC stimulator or PDE-5 inhibitor, have not been introduced.

---

Important Clinical Pearl

Vericiguat is best remembered as a drug for the “recently worsening HFrEF patient.”

It is not one of the routine four foundational pillars of HFrEF therapy.

A useful exam-oriented sequence is:

HFrEF + recent worsening HF + optimized GDMT → think about vericiguat.

---

High-Yield Summary

Drug: Vericiguat

Drug class: Soluble guanylate cyclase (sGC) stimulator

Pathway: NO–sGC–cGMP pathway

Main clinical setting: Symptomatic HFrEF with recent worsening heart failure despite appropriate GDMT

Key trial: VICTORIA

Trial EF criterion: LVEF <45%

Starting dose: 2.5 mg once daily with food

Target dose: 10 mg once daily

Major adverse effects: Hypotension and anemia

Important contraindications: Pregnancy and concomitant use of another sGC stimulator

Important interaction/caution: Concomitant PDE-5 inhibitor use is not recommended because of the risk of hypotension

---

Take-Home Message

Vericiguat provides a distinct therapeutic strategy for patients with HFrEF by targeting impaired nitric oxide–soluble guanylate cyclase–cGMP signaling.

Its place in modern heart failure therapy is most relevant after a worsening HF event in patients who remain at substantial risk despite guideline-directed medical therapy.

The key concept is patient selection. Vericiguat should not replace the foundational therapies of HFrEF. Instead, it provides an additional option for selected high-risk patients, particularly those with recent hospitalization or other clinically significant worsening of heart failure.

For clinicians and medical students, remember the association:

Vericiguat → sGC stimulation → ↑ cGMP → recently worsening HFrEF → VICTORIA trial.

For more cardiology and echocardiography educational content:

drmusmanjaved.com